Primary Site >> Stomach Cancer
Gene >> CTLA4
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. PMID: 16328385 |
Ref: Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. PMID: 17487401 Ref: CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. PMID: 18031393 |
Ref: Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. PMID: 19688278 Ref: CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. PMID: 20538028 |
Ref: [Ipilimumab]. PMID: 24047771 Ref: Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: a meta-analysis. PMID: 24376736 |
Ref: Analysis of promoter methylation, polymorphism and expression profile of cytotoxic T-lymphocyte-associated antigen-4 in patients with gastric cancer. PMID: 25267951 |
Ref: Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. PMID: 25385008 |
Ref: A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer. PMID: 26644313 Ref: [Progression of immunotherapy in gastric cancer]. PMID: 26831889 Ref: Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. PMID: 27039171 Ref: Therapeutic Antibodies in Cancer Therapy. PMID: 27236554 Ref: FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). PMID: 27245147 Ref: The first review study on association of DNA methylation with gastric cancer in Iranian population. PMID: 27268620 Ref: [Cancer immunotherapy: Rational and recent breakthroughs]. PMID: 27370898 Ref: Immunotherapy for Gastroesophageal Cancer. PMID: 27669318 |
Ref: Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. PMID: 27241062 Ref: Immunotherapy for gastric cancers: emerging role and future perspectives. PMID: 28349740 Ref: Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. PMID: 28655793 Ref: Multifocal gastric adenocarcinoma in a patient with LRBA deficiency. PMID: 28720148 Ref: PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. PMID: 28757801 Ref: Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. PMID: 28781967 Ref: Monoclonal Antibodies for the Treatment of Cancer. PMID: 29061772 Ref: [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors]. PMID: 29239193 |
Ref: Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines. PMID: 29374027 Ref: Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. PMID: 29542354 Ref: Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. PMID: 29705787 Ref: Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. PMID: 29729943 Ref: Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. PMID: 29730461 Ref: Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review). PMID: 29786110 Ref: The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. PMID: 30018250 Ref: Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis. PMID: 30138920 Ref: Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. PMID: 30173350 Ref: Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. PMID: 30250467 |